Ista Tries To Void Vitrase NME Status: Will Less Exclusivity Mean More?
Executive Summary
Ista is requesting its hyaluronidase product Vitrase be downgraded from new molecular entity status in order to obtain more meaningful exclusivity
You may also be interested in...
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics
USP Human Growth Hormone Monographs Issued; Generics Status Unresolved
U.S. Pharmacopeia's release of monographs on human growth hormone appears unlikely to significantly advance the debate over an abbreviated pathway for HGH follow-on products